Stocks To Buy Now

Blog


On the Move Systems (OMVS) Points Out Trends Driving the Need for Shared Economy Solutions

Globalization was the rage in the 1990s, with multinational free trade pacts leading to offshore manufacturing and the presumed death of American heavy industry. Twenty years later, the pendulum has swung the other way and returning manufacturers needing to move raw materials and finished goods are fueling demand for On the Move Systems’ (OMVS) upcoming Uber-for-Trucking shared economy platform.

Distance, speed and cost are among the factors feeding de-globalization and re-shoring. Moving manufacturing offshore has created lengthy supply chains that have proved difficult to manage and maintain. Second, extended globalization has made it harder for companies to react quickly to changing market conditions. Finally, labor and energy costs in China and other once-cheap markets have increased, making them less desirable. As a result, manufacturers are increasingly moving or considering moving operations back to the United States for greater cost and quality control.

“Bringing manufacturing back to the U.S. is not only good for America but for trucking as well,” said OMVS CEO Robert Wilson. “As manufacturing returns, the demand for trucking services also rises, which means national trucking companies have a greater need to connect with local drivers, and vice-versa, to optimize routes and schedules. The growing re-shoring trend can therefore greatly strengthen our shared economy business plan as our upcoming on-demand platform will enable truckers to make the best possible use of resources.”

OMVS’s cutting-edge shared economy platform will enable truckers to not only build networks, but maximize equipment utilization, recruit drivers and effectively price their services. Shared economy services are estimated to be a $450 billion market.

For more information on OMVS, please visit www.onthemovesystems.com

Let us hear your thoughts: On the Move Systems Corp. Message Board

From Our Blog

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

March 31, 2026

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]

Rotate your device 90° to view site.